Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a poor prognosis. In resectable PDAC, the recurrence rate is still high even when surgery and adjuvant chemotherapy (CT) are applied. Regional lymph node metastasis and positive margins are associated with higher recurrence risk and wo...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-09, Vol.11, p.660215-660215
Main Authors: Xing, Jiazhang, Yang, Bo, Hou, Xiaorong, Jia, Ning, Gong, Xiaolei, Li, Xiaoyuan, Zhou, Na, Cheng, Yuejuan, Bai, Chunmei
Format: Article
Language:English
Subjects:
adjuvant chemoradiation
adjuvant chemotherapy
lymph node metastasis
Oncology
pancreatic ductal adenocarcinoma
R1 resection
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a poor prognosis. In resectable PDAC, the recurrence rate is still high even when surgery and adjuvant chemotherapy (CT) are applied. Regional lymph node metastasis and positive margins are associated with higher recurrence risk and worse survival. Adjuvant radiotherapy has been explored, but its efficacy remains controversial. In recent years, some characteristics have been reported to stratify patients who may benefit from adjuvant chemoradiation (CRT), such as lymph node metastasis and margin status. Adjuvant chemotherapy followed by chemoradiation (CT-CRT) was also proposed. A total of 266 patients with resectable PDAC who have lymph node metastasis or R1 resection after surgery were enrolled. In multivariate Cox regression analyses, pancreatic body or tail tumor location (HR 0.433, p
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.660215